by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham

Slides:



Advertisements
Similar presentations
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation by Fumiaki Banno, Anil K. Chauhan, Koichi Kokame,
Advertisements

Activation of αIIbβ3 is a sufficient but also an imperative prerequisite for activation of α2β1 on platelets by Gerlinde R. Van de Walle, Anne Schoolmeester,
by Matt W. Goschnick, Lai-Man Lau, Janet L. Wee, Yong S. Liu, P
Occlusive thrombi arise in mammals but not birds in response to arterial injury: evolutionary insight into human cardiovascular disease by Alec A. Schmaier,
VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13 by Koichi Kokame, Masanori Matsumoto, Yoshihiro.
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,
Vessel wall BAMBI contributes to hemostasis and thrombus stability
Shielding the front-strand β3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibα by Arnaud Bonnefoy, Hiroshi Yamamoto,
by Kesheng Dai, Richard Bodnar, Michael C. Berndt, and Xiaoping Du
Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3 by Cindy L. Yap, Karen.
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow by.
Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II by Domenick J. Falcone, Wolfgang Borth,
by Nayna Mistry, Susan L. Cranmer, Yuping Yuan, Pierre Mangin, Sacha M
ADAP interactions with talin and kindlin promote platelet integrin αIIbβ3 activation and stable fibrinogen binding by Ana Kasirer-Friede, Jian Kang, Bryan.
by Zhengyan Wang, Tina M. Leisner, and Leslie V. Parise
Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection by Shokrollah Elahi, Toshiro Niki, Mitsuomi Hirashima,
by Jörg Hartleib, Nicola Köhler, Richard B. Dickinson, Gursharan S
Exposure to fluid shear stress modulates the ability of endothelial cells to recruit neutrophils in response to tumor necrosis factor-α: a basis for local.
Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease by.
A role for the thiol isomerase protein ERP5 in platelet function
Metalloproteinases Are Involved in Lipopolysaccharide– and Tumor Necrosis Factor-–Mediated Regulation of CXCR1 and CXCR2 Chemokine Receptor Expression.
Inhibition of Platelet GPIbα and Promotion of Melanoma Metastasis
Indrajeet Singh, Efrosyni Themistou, Lionel Porcar, Sriram Neelamegham 
by Harish Shankaran, Paschalis Alexandridis, and Sriram Neelamegham
Hyaluronate-Enhanced Hematopoiesis: Two Different Receptors Trigger the Release of Interleukin-1β and Interleukin-6 From Bone Marrow Macrophages by Sophia.
Β1 integrin−mediated signals are required for platelet granule secretion and hemostasis in mouse by Tobias Petzold, Raphael Ruppert, Dharmendra Pandey,
Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression by Søren Skov, Klaus Rieneck,
by Xingming Deng, Fengqin Gao, and W. Stratford May
Apoptotic Vascular Endothelial Cells Become Procoagulant
by James T. B. Crawley, Rens de Groot, Yaozu Xiang, Brenda M
C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.
by Guang Yang, Shu-Ching Huang, Jane Y. Wu, and Edward J. Benz
Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent.
Α-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4 by Lucinda Furci, Francesca Sironi, Monica Tolazzi,
by Asim Khwaja, and Louise Tatton
Brian Savage, Enrique Saldívar, Zaverio M Ruggeri  Cell 
Interaction of kindlin-3 and β2-integrins differentially regulates neutrophil recruitment and NET release in mice by Zhen Xu, Jiayi Cai, Juan Gao, Gilbert.
Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,
Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations by Bénédicte Dumont, Dominique Lasne, Chantal Rothschild,
by Thomas D. Nightingale, Krupa Pattni, Alistair N. Hume, Miguel C
Protease-Activated Receptor-2 (PAR-2) Expression in Human Fibroblasts is Regulated by Growth Factors and Extracellular Matrix  Barry L. Gruber, Mary J.
A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13 by Minyun Zhou, Xianchi Dong, Carsten Baldauf, Hua Chen,
Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha,
by Reuben Kapur, Ryan Cooper, Lei Zhang, and David A. Williams
Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors by Danuta Jarocha, Karen K. Vo, Randolph.
Volume 97, Issue 9, Pages (November 2009)
A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b by Hua Zhou, Henrik Olsen, Edward So, Emmanuel.
Role of calcium in regulating the intra- and extracellular cleavage of von Willebrand factor by the protease ADAMTS13 by Shobhit Gogia, Anju Kelkar, Changjie.
Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production by Soe Soe Htwe, Hidenori Wake, Keyue.
Volume 22, Issue 12, Pages (March 2018)
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
by Silvia Mele, Stephen Devereux, Andrea G
Nachiket Shembekar, Hongxing Hu, David Eustace, Christoph A. Merten 
Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow  Brian Savage, Fanny Almus-Jacobs, Zaverio M Ruggeri 
Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects by Constance C. F. M. J. Baaten, Frauke Swieringa, Tomasz Misztal,
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib by Alexander P. Bye, Amanda J. Unsworth,
T exosomes bind MAdCAM-1 via RA-increased integrin α4β7.
Exosomal regulation of lymphocyte homing to the gut
ELMO1 deficiency enhances platelet function
The von Willebrand Factor protein showing various functional domains that have been mapped to regions of the cDNA. The von Willebrand Factor protein showing.
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor by Gauthami Jalagadugula, Lawrence.
Volume 8, Issue 2, Pages (February 1998)
Volume 21, Issue 4, Pages (April 2013)
Volume 11, Issue 13, Pages (July 2001)
Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration  Yan Li, John Fung, Feng Lin  Molecular Therapy 
by Fabian C. Verbij, Nicoletta Sorvillo, Paul H. P
Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S by José A. Fernández, Xiao Xu, Ranjeet K.
Presentation transcript:

by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham BloodAdv Volume 3(7):957-968 April 9, 2019 © 2019 by The American Society of Hematology

Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Role of VWF-A2 in self-association. Role of VWF-A2 in self-association. (A) Schematic of VWF proteins. A1 domain is deleted in ΔA1-VWF. WT protein (WT-VWF) has vicinal Cys in the A2 domain. The disulfide bond links the N and C terminus of VWF-A2 in Lock-VWF. (B) Protein multimer distribution of VWF variants expressed in HEK293T-furin cells. (C) Time course of VWF cleavage by 1 U/mL ADAMTS13 in the presence of 1.6 M urea at 37°C. Minimal cleavage of Lock-VWF is noted. (D-E) Five × 107/mL washed platelets were shear mixed at 9600/s in a cone-plate viscometer along with 10 μg/mL ΔA1-488, either in the absence of VWF or upon addition of 10 μg/mL WT-VWF or Lock-VWF. Buffer calcium concentration was varied from 0 to 1.5M CaCl2 (EDTA was not added). VWF self-association (D) and percentage platelet activation (E) were measured using flow cytometry for samples withdrawn at 5 minutes. VWF self-association quantifies the percentage of platelets binding more than basal (t = 0) levels of Alexa 488-conjugated ΔA1-VWF (ΔA1-488). Platelet activation measures the percentage of platelets binding PE-conjugated Annexin V. (F-G) VWF self-association (F) and platelet activation (G) triggered by WT-VWF was blocked by 20 µg/mL mAbs AK2 (anti-GpIbα) and AVW-3 (anti-VWF A1 domain). Data in panels D-G are from 3 to 4 independents runs, each containing 3 technical replicates. *P < .05 with respect to all other treatments at that calcium concentration. VWF self-association and platelet activation are higher for runs performed with WT-VWF compared with Lock-VWF. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Microfluidics thrombus formation assay. Microfluidics thrombus formation assay. (A-C) Washed blood containing fluorescent-labeled platelets and 10 µg/mL WT-VWF/Lock-VWF were perfused at a wall shear rate of 500/s over substrates adsorbed with 40 µg/mL ΔA1-VWF. (A) Thrombus formation was measured based on fluorescence intensity in the field of view. (B) Representative images of platelet accumulation on ΔA1-VWF substrate shows greater accumulation in the case of WT-VWF. (C) Platelet accumulation on ΔA1-VWF in runs containing WT-VWF was blocked by mAbs against GpIbα (AK2), VWF-A1 (AVW-3) and VWF-D’D3 (clone DD3.1). (D-E) Thrombus formation on collagen substrate in the presence of 10 µg/mL WT-VWF or Lock-VWF. (D) Wall shear rate was varied: 400/s, 1000/s, and 2000/s. Thrombus formation was blocked by mAbs AK2, AVW-3, and DD3.1, at 1000/s. (E) Representative images of thrombus formation at 3 minutes at different shears. All microfluidics assays were performed 3 to 4 times, each with 2 to 4 repeats. *P < .05 with respect to all other treatments. (B,E) Scale bars, 100 µm. Platelets stained using BCECF-AM. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

VWF fiber formation on collagen in stenosed channel. VWF fiber formation on collagen in stenosed channel. (A) Schematic design of flow chamber used for fiber formation assay. (B) Citrated human plasma, supplemented with either 1.5 M CaCl2 or 10 mM EDTA, was perfused over type I collagen substrates for 10 minutes at 100 000/s. A FITC-coupled anti-VWF Ab was added postperfusion to visualize VWF fibers. Representative images in different parts of the flow chamber are show. VWF fiber formation was promoted upon calcium chelation. (C) Fluorescence intensity of fibers formed was measured in different parts of the flow device: inlet transition from 100 µm to 50 µm width, 50 μm middle section, and outlet from 50 μm to 100 μm as shown in panel B. (D-F) VWF variants (WT and Lock) were created with a Cerulean (CFP)-insert prior to the A1 domain in WT and Lock-VWF (D). Protein multimer distribution following expression in HEK293T-furin cells (E), and susceptibility to proteolysis by 1 U/mL ADAMTS13 overnight at 37°C in the presence of 1.6 M urea (F). (G-H) Human plasma was mixed with 5 μg/mL WT-Cer or Lock-Cer VWF variants in the presence of 10 mM EDTA, and perfused over collagen at 100 000/s. Fiber formation was measured in different regions of the flow device. FITC-conjugated anti-VWF Ab measured total VWF deposits, and cerulean fluorescence assayed only recombinant-protein accumulation. Representative images (G) and quantitative analysis (H) are presented. (I) Approximately10 µg/mL WT- or Lock-VWF were repeatedly perfused in the collagen coated stenosed flow chamber at a maximum wall shear rate of 100 000/s for 10 minutes. This allowed 20 passages of VWF through the flow constriction. Solution concentration of VWF was measured before and after shear application. Greater amounts of WT-VWF was lost compared with Lock-VWF. All microfluidics assays were performed 3 times, each with 2 to 4 repeats. *P < .05 with respect to all other treatments. VWF self-association was diminished in the presence of calcium, and upon use of Lock-variants. (B,G) Scale bars, 50 µm; VWF labeled with FITC (green) or Ceruelan (cyan). Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Self-association of VWD type 2A and calcium-binding–deficient mutants. Self-association of VWD type 2A and calcium-binding–deficient mutants. (A) Multimer distribution of WT- and mutant-VWF produced in HEK293T-furin cells. (B) A total of 1 U/mL ADAMTS13 was added to various proteins for 4 hours in the absence or presence of 1.6 M urea. VWF proteolysis was greater for the mutant molecules, and this was evident even in the absence of urea. (C-D) PRP from normal human donors was diluted 50-fold and shear mixed with 10 μg/mL ΔA1-488 at 9600/s in a viscometer in the absence of supplemented calcium, along with either 5 μg/mL WT-VWF, D1498A, or R1597W. VWF self-association (C) and platelet activation (D) were measured identically to Figure 1. (E) Thrombus formation on collagen type I was measured at 1000/s following methods in Figure 2D-E. Greater thrombus formation was noted upon supplementing washed blood with D1498A and R1597W (either 2 or 4 µg/mL) compared with WT-VWF. (F) Representative images of thrombus formation at 3 minutes. Assays were performed 3 to 4 times, each with 2 to 4 repeats. *P < .05 with respect to all other treatments. Scale bars in panel F, 100 µm; BCECF platelet stain. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Molecular mechanism of VWF self-association. Molecular mechanism of VWF self-association. (A) Four VWF mutants lacking the A1 domain were produced, and each was labeled with Alexa 647. (B-E) PRP was diluted 50-fold into HEPES buffer containing one of the ΔA1-Alexa 647 variants (2.5 µg/mL), along with either 5 µg/mL WT-VWF (B-C) or Lock-VWF (D-E). The mixture was sheared at 9600/s using a viscometer in buffer containing either no exogenous calcium (B,D) or physiological calcium (C,E). VWF self-association was measured based on ΔA1-Alexa 647 binding to platelets using flow cytometry. VWF self-association was observed even when the ΔA1-proteins were sheared in the presence of Lock-VWF (lower panels), indicating that the unfolded A2 domain may bind other VWF regions also, in addition to homotypic association. *P < .05 with respect to all other treatments at indicated times. Data are from 3 repeats. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Inhibitors of VWF self-association. Inhibitors of VWF self-association. (A-B) Studies similar to Figure 5B-C were performed, by shearing 1:50 diluted PRP with 2.5 µg/mL ΔA1-647 and 5 µg/mL WT-VWF. HEPES buffer was replaced by VWF-deficient plasma in one case. In other cases, 500µg/mL ApoA-I or HDL was added. Studies were performed in the absence (A) and presence (B) of exogenous calcium. VWF self-association was reduced by lipoproteins in panel A. *P < .05 with respect to other treatments at indicated times. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology

Conceptual model of VWF self-association. Conceptual model of VWF self-association. The A2 domain of WT/native VWF is in a closed conformation. The unfolding of this domain is promoted by fluid shear, and enhanced upon depleting calcium and mutating A2 to prevent calcium binding. Such shear mediated A2-unfolding promotes VWF self-association on platelet GpIbα thus enhancing SIPAct. This also augments VWF binding to collagen, promoting thrombus growth. The introduction of a disulfide bond across A2 locks/seals the domain, preventing A2-unfolding and VWF self-association. Changjie Zhang et al. Blood Adv 2019;3:957-968 © 2019 by The American Society of Hematology